drugset / Trial / NCT05756556

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

NCT05756556

Phase 2 Suspended 68 enrolled ImmVira Pharma Co. Ltd
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of T3011 in combination with Cobimetinib in patients with advanced melanoma.

Timeline

Start
2024-06-30
Primary completion
2026-12-31
Completion
2027-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cobimetinib Small molecule 60 mg Oral
Subject T3011 Other / unclassified 1e+08 unknown Other

Indications